Navigation Links
BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
Date:5/8/2009

or less. The primary analysis population consisted of patients with confirmed influenza A. Approximately 79 percent of subjects with influenza A (H1N1) demonstrated the H274Y mutation. This mutation has been associated with resistance to the anti-viral treatment oseltamivir.(2)

Financial Results for the First Quarter Ended March 31, 2009

For the three months ended March 31, 2009, the Company reported collaborative and other research and development revenues of $4.4 million, compared to $10.8 million for the three months ended March 31, 2008. This decrease was driven by a reduction in revenue from the contract with the HHS for the development of peramivir. In addition, the Company recognized less revenue during the quarter related to its deferred collaboration arrangements.

Research and development (R&D) expenses were $11.3 million for the three months ended March 31, 2009, compared to $21.9 million for the three months ended March 31, 2008. The decrease in R&D expenses was primarily attributable to a reduction in clinical development costs associated with the peramivir program, a reduction in manufacturing costs associated with both the peramivir and forodesine programs and a reduction in costs incurred related to the Company's preclinical programs.

General and administrative (G&A) expenses were $2.5 million for the three months ended March 31, 2009, compared to $2.9 million for the three months ended March 31, 2008. The lower expenses were primarily due to decreases in professional fees and operating costs.

Net loss for the quarter ended March 31, 2009, was $9.3 million, or $0.24 per share, compared to a net loss for the quarter ended March 31, 2008, of $13.1 million, or $0.34 per share.

As of March 31, 2009, the Company held cash, cash equivalents and investments of $54.2 million. BioCryst continues to expect the Company's net cash u
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
2. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
3. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
4. BioCryst Updates Peramivir Clinical Development Plan
5. BioCryst Provides Forodesine HCl Update
6. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
7. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
8. USAID Provides $5M in Emergency Support as Swine Flu Spreads
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
10. Strativa Pharmaceuticals Provides Product Pipeline Update
11. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015  Rosa & Co. LLC, a drug development ... today announced its pleasure to be lead partner for ... Systems Pharmacology (QSP). The conference focuses on uses and ... Logo - ... Rosa,s lead sponsorship is the second of ...
(Date:4/28/2015)... -- Boston Scientific Corporation (NYSE: BSX ) generated ... ended March 31, 2015, compared to the company,s ... $1.800 billion.  This represents 6 percent operational revenue ... flat revenue on a reported basis, all compared ... adjusted earnings per share of $0.21 for the ...
(Date:4/28/2015)... INDIANAPOLIS , April 28, 2015  People with ... receive a heart stent are prescribed an oral antiplatelet (OAP) ... blood clot in their heart stent (stent thrombosis), or even ... that 52 percent of 275 ACS patients who were currently ... they take their prescribed OAP therapy, even though most of ...
Breaking Medicine Technology:Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 2Rosa & Co. is the Lead Partner for the Quantitative Systems Pharmacology (QSP) Congress in Basel, Switzerland and Will Present the Keynote Address 3Boston Scientific Announces Results for First Quarter 2015 2Boston Scientific Announces Results for First Quarter 2015 3Boston Scientific Announces Results for First Quarter 2015 4Boston Scientific Announces Results for First Quarter 2015 5Boston Scientific Announces Results for First Quarter 2015 6Boston Scientific Announces Results for First Quarter 2015 7Boston Scientific Announces Results for First Quarter 2015 8Boston Scientific Announces Results for First Quarter 2015 9Boston Scientific Announces Results for First Quarter 2015 10Boston Scientific Announces Results for First Quarter 2015 11Boston Scientific Announces Results for First Quarter 2015 12Boston Scientific Announces Results for First Quarter 2015 13Boston Scientific Announces Results for First Quarter 2015 14Boston Scientific Announces Results for First Quarter 2015 15Boston Scientific Announces Results for First Quarter 2015 16Boston Scientific Announces Results for First Quarter 2015 17Boston Scientific Announces Results for First Quarter 2015 18Boston Scientific Announces Results for First Quarter 2015 19Boston Scientific Announces Results for First Quarter 2015 20Boston Scientific Announces Results for First Quarter 2015 21Boston Scientific Announces Results for First Quarter 2015 22Boston Scientific Announces Results for First Quarter 2015 23Boston Scientific Announces Results for First Quarter 2015 24Boston Scientific Announces Results for First Quarter 2015 25Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 2Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 3Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 4Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 5Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 6Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 7Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 8Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 9
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 2DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 3DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 4DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 5DATATRAK Attends 22nd Annual DIA EuroMeeting in Monaco 6HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 2HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 3HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 4HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 5HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 6HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures 7
(Date:4/28/2015)... As the Muscular Dystrophy Association ... programs, the organization has hired Scientific Program Officer ... from Fidelity Biosciences Research Initiative where, as Associate ... neurodegenerative diseases such as Alzheimer’s Disease, and organized ... at Fidelity, she was a junior faculty member ...
(Date:4/28/2015)... Celebrating women has become a tradition at ... third year that all things mom and female will be ... is offering some great specials Special discounts ... year could there be to focus on woman," states Marla ... this is a terrific time for it. And the special ...
(Date:4/28/2015)... 28, 2015 The buyer power score ... of 5, indicating a medium level of buyer power ... suppliers have equal power during negotiations. One factor helping ... purchasing a health insurance policy from an insurance carrier ... buyers can choose to self-fund their own policy or ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 Dead or damaged ... and their property. In many cases, tree removal by a ... way to eliminate the threat. , In their ... of tree removal available to property owners today. Each method ... for a job well done. , The article states that, ...
(Date:4/28/2015)... DC (PRWEB) April 28, 2015 ... Medicare-Medicaid dual eligibles reached 2.2 million in April, ... Inc.’s (AIS) new Medicare-Medicaid Dual Eligibles Database ... programs and plans serving the dual-eligible community. This ... Eligibles Database began tracking initiatives in January, but ...
Breaking Medicine News(10 mins):Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Commack Massage Therapy and Wellness Day Spa Dedicates Time To Celebrate Women 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4Health News:Tree Removal Methods and Services Discussed in Recent Article by Precision Tree Services 2Health News:Enrollment in Duals Programs Increases 14%, New AIS Database Finds 2
... Since Sept. 11, it has become increasingly common ... or "infidels" to hell, but this has never ... State University professor who recently published a first-of-its-kind book ... Western writers believe condemnation and dehumanization of non-Muslims make ...
... , FRIDAY, May 18 (HealthDay News) -- Personal genetic testing does ... study finds. The opportunities for people to undergo genetic tests ... increasing, and some experts fear this might lead to overuse of ... in the journal Genetics in Medicine , looked at 217 ...
... The surgical team at the Montreal Heart Institute (MHI) achieved ... sutureless aortic valve replacement through a thoracic incision just five ... this innovative procedure, which was performed by cardiac surgeons Denis ... after their operations. A novel combination ...
... , FRIDAY, May 18 (HealthDay News) -- Inflammation caused ... a new study finds. The condition -- formally known ... at the end of the esophagus doesn,t close properly, allowing ... it. GERD can lead to changes in the tissue ...
... 18 (HealthDay News) -- Eating a healthy, calorie-controlled diet during ... the risk of obstetric complications, researchers report. In Europe ... gain more than the recommended weight during pregnancy and this ... problems, according to background information in the study published online ...
... Chevy Chase, MDThe Endocrine Society,s new scientific statement ... of both the basic and clinical evidence related ... statement addresses current research regarding the associations of ... conditions and maternal/fetal health. Vitamin D is ...
Cached Medicine News:Health News:What does Islam say about the fate of others? 2Health News:Gene Tests May Not Drive Patients to More Medical Care 2Health News:A North American first at the Montreal Heart Institute 2Health News:Chronic Heartburn May Boost Risk for Esophageal Cancer 2Health News:Healthy Dieting in Pregnancy May Be Helpful 2Health News:Experts call for clinical trials to test non-skeletal benefits of vitamin D 2
The under-patient design of the pediatric full access blanket warms even the tiniest patients while allowing full access for surgeons and staff....
Similar to Model 530, but just 37 inches long and with only one drape....
This pediatric blanket is a smaller version of the full body blanket, providing warmth to smaller patients during recovery....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Medicine Products: